ClinicalTrials.gg
CompletedNCT05439473Updated Oct 26, 2026

Evaluation of the Efficacy and Safety of Curalin as Add-On Therapy in Adults With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Curalin in Type2 Diabetes, sponsored by CuraLife. Completed at 1 site in Israel. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CuraLife · Phase 2, Interventional, and Supportive care

How we know

Updated Oct 26, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 223 studies in Diabetes Mellitus, Type 2 with a site in Israel — 10 open to participants now, 16 under way, 7 of them phase 3. Diabetes Mellitus, Type 2 · Israel.

Enrollment
172nd of 197
36 · median 343
Started
2021
with 5 others
Phase 2
19 of 223
none open now
Registered
198th of 223
by date

Among the 223 studies in Diabetes Mellitus, Type 2 with a site in Israel, this one is the 172nd largest by enrollment of the 197 interventional ones that give a count, is one of 6 that started in 2021, is one of 19 in phase 2, and was the 198th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 223 studies in Diabetes Mellitus, Type 2 with a site in Israel are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Diabetes Mellitus, Type 2 with a site in Israel, or all of them as a file.
02

Study summary

Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus

Read the detailed description

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus

03

Conditions studied

  • Type2 Diabetes

Browse trials for

Keywords

  • Diabetes
  • Type 2 Diabetes
  • placebo
  • Curalin
  • CuraLife
  • Momordica Charantia
  • Gymnema Sylvestre
  • Trigonella Foenum Graecum
  • Curcuma Longa
  • Emblica Officinalis
  • Swertia Chirata
  • Picrorhiza Kurroa
  • Syzygium Cumini/ Eugenia Jambolana
  • Cinnamomum Zeylanicum
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 36 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

CuraLife is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written is obtained.
  • Adult patients (18-85 years of age) with Type II diabetes mellitus.
  • at screening is 8% - 11%.
  • (BMI)>25.
  • Stable body weight (±10%) within the 3 months preceding study entry.
  • Patients were steadily treated with anti-diabetic medications, such as: GLP-1, Glucophage DPP-4 inhibitor or SGLT-2 inhibitor for at least 3 months or more prior to study entry.
  • The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow up evaluation as specified in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Patients who have been using Curalin
  • Persons with known sensitivity to any of the components of the Curalin product.
  • The patient has any uncontrolled medical condition (treated or untreated).
  • Patients with renal insufficiency ( [GFR]≤30 mL/min/1.73m2).
  • Pregnant or lactating women. Women of child bearing potential will be administered a urine pregnancy test at study entry. All study participants will confirm their willingness to use throughout the study.
  • Patients deemed by the Investigator as unable to complete study participation.
  • Patients currently treated with insulin or those that have been treated with insulin for more than 10 days in the 3 months prior to study entry.
  • Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, local, dermal and inhaled , and or immunomodulating agents for more than a month prior to study entry, or during the study.
  • Patient participated in a clinical study ( study drug or study device) within 30 days of the study entry.
  • less than 1 year.
  • History of stroke, , or myocardial infarction within six months prior to screening.
  • Patients with uncontrolled hypertension defined as a systolic blood pressure ≥180 mmHg or a diastolic blood pressure ≥100mmHg.
  • Patients who have thyroid stimulating hormone (TSH) levels >1.5 times the .
  • Patients with significant liver disease or liver function impairment defined as any of the following; cirrhosis, hepatitis, biliary obstruction with hyperbilirubinemia (total >2 times the upper limit of normal) and (AST) or alanine aminotransferase levels (ALT) >3 times the upper limit of normal.
  • Patients with creatine kinase concentrations > 10 times the upper limit of normal or creatine kinase elevation due to known muscle disease at visit 1 (screening 1).
  • Laboratory abnormalities at screening including:
  • Potassium > 5.5 mEq/L
  • Sodium ≤ 130 mEq/L
  • under 10 g/dl for Women or Under 11 g/dl for man.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

06

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Dietary Supplement: Curalin

  • Active comparator
    Treatment

    Dietary Supplement: Curalin

Interventions

  • Dietary supplementCuralin

    Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.

07

What researchers measure

Primary outcomes

  1. Effect of treatment with Curalin on the change in plasma HbA1c

    The primary objective of this study is to evaluate the effect of treatment with Curalin on the change in plasma HbA1c. Glycated hemoglobin (HbA1c) is a form of hemoglobin that is measured primarily to identify the three-month average plasma glucose concentration. The primary endpoint of the study is HbA1c at 1 month. Blood for HbA1c will be taken at Screening, and M1/Termination of Study. HbA1c level will be ascertained at the local lab, according to the lab's operating procedures Rate of patients that significantly improved their HbA1c levels at least 0.5%.

    Time frame: 1 month

Secondary outcomes

  1. Effect of Curalin on Fructosamin based on blood tests

    To evaluate the effect of Curalin on Fructosamin level based on blood tests(mmol/L)

    Time frame: 1 month

  2. Efect of Curalin on Fasting Blood Glucose Blood for glucose assessment

    To evaluate the effect of Curalin on Fasting Blood Glucose Blood for glucose assessment will be taken after a 12 hour fast at Screening, Baseline, and M1/Termination of PC Study. Fasting blood glucose level will be ascertained at the local site lab, according to the site's operating procedures. In addition, participants will self-monitor their blood glucose levels at home once a week using a blood glucose meter.

    Time frame: 1 month

  3. Safety of Curalin as assessed by adverse events

    To evaluate the safety of Curalin as assessed by adverse events, including the following: * Fasting blood chemistry including (in addition to the efficacy variables of Fructosamine): HbA1c, glucose, urea, creatinine, phosphorus, calcium, potassium, albumin, sodium (Na+) and liver function tests (ALT, AST, bilirubin and GGT), GFR, CBC. * Vital Signs including (in addition to the efficacy variable of blood pressure): pulse rate, body temperature

    Time frame: 1 month

08

Study locations

1 site
  • DMC
    Tel Aviv, Israel
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Apr 2022, 7 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2021
First posted
Jun 30, 2022
StartActual
Aug 3, 2021
Primary completionActual
Apr 1, 2022
CompletionActual
May 1, 2022
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
51→36
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Enrollment 51→36
    + 2 other changes: design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05439473
Lead sponsor
CuraLife
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Aug 3, 2021
Primary completion
Apr 1, 2022
Completion
May 1, 2022
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion